Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Edgewise Therapeutics (EWTX) Income from Continuing Operations (2020 - 2026)

Edgewise Therapeutics has reported Income from Continuing Operations over the past 7 years, most recently at 49013000.0 for Q1 2026.

  • Quarterly results put Income from Continuing Operations at 49013000.0 for Q1 2026, down 20.14% from a year ago — trailing twelve months through Mar 2026 was 176010000.0 (down 20.48% YoY), and the annual figure for FY2025 was 167795000.0, down 25.4%.
  • Income from Continuing Operations reached 49013000.0 in Q1 2026 per EWTX's latest filing, up from 50216000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 14660000.0 in Q1 2022 and bottomed at 50216000.0 in Q4 2025.
  • Median Income from Continuing Operations over the past 5 years was 30143000.0 (2023), compared with a mean of 30495529.41.
  • The largest annual shift saw Income from Continuing Operations tumbled 115.11% in 2022 before it dropped 14.66% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 19415000.0 in 2022, then tumbled by 55.26% to 30143000.0 in 2023, then plummeted by 31.58% to 39662000.0 in 2024, then decreased by 26.61% to 50216000.0 in 2025, then grew by 2.4% to 49013000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for EWTX at 49013000.0 in Q1 2026, 50216000.0 in Q4 2025, and 40666000.0 in Q3 2025.